Influenza
1.0K views | +0 today
Influenza
Flu in all Forms, Be Informed...Not Panicked.
Your new post is loading...
Your new post is loading...
Rescooped by Mel Melendrez-Vallard from Market Research Reports
Scoop.it!

Research Report on China Avian Influenza Vaccine Industry 2014-2018

Research Report on China Avian Influenza Vaccine Industry, 2014-2018 under Pharmaceuticals is now available with LifeScienceIndustryResearch.com. This life sciences market research report 22859 is priced at US $ 1800 for a single user PDF license.

Via Gloria Rosenow
more...
Gloria Rosenow's curator insight, September 20, 2014 9:38 AM

The Report “Research Report on China Avian Influenza Vaccine Industry, 2014-2018” by China Research and Intelligence is now available at lifescienceindustryresearch.com. Contact sales@lifescienceindustryresearch.com Phone with “Research Report on China Avian Influenza Vaccine Industry, 2014-2018″ in subject line and your contact details to purchase this report or get your questions answered.


The collection of ‘Pharmaceuticals’ market research reports has a new addition of “Research Report on China Avian Influenza Vaccine Industry, 2014-2018” on lifescienceindustryresearch.com.

 

Many countries choose to kill all infected poultry to control avian influenza, instead of immunizations. The total number of poultry exceeds 10 billion in China. Epidemic diseases, which are difficult to control, will result in huge losses. Therefore, it is quite necessary to immunize the poultry with avian influenza vaccines.

 

Avian influenza vaccines have been used for more than 10 years in China. Some poultry farms in China began to use H5N1 avian influenza vaccines voluntarily 10 years ago without compulsory requirements. Chinese avian influenza vaccine industry was in the initial stage in 20012005 with upcoming problems. To resolve these problems, the Ministry of Agriculture of China sets up an entry barrier for the avian influenza vaccine production and imposes strict supervision. The Ministry of Agriculture of China established strict regulations on the production and sales of avian influenza vaccines. For instance, avian influenza vaccines must be produced in workshops that are in compliance with GMP and inspected every year.

 

In China, the subsidy provided by the government over killing the infected poultry is CNY 10 per bird. In case of serious epidemic diseases, the subsidy amount will be higher.


Price for single user license is US $1800 and corporate user

license is US $2700


Inquire for discount on this report @ http://www.lifescienceindustryresearch.com/discount?rname=22859.

 

In 2013, the live stock volume of laying hens in China was about 1.4 billion while that of broilers was approximately 10 billion. The output volume of eggs in China was 28.76 million tons in 2013, up by 0.5% YOY. According to National Compulsory Immunization Plan of Animal Epidemic Diseases 2013 issued by Ministry of Agriculture of China, the government conducts compulsory immunizations against 4 diseases, including highly pathogenic avian influenza. The government is responsible for the expenses. In 2013, the market size of avian influenza vaccines exceeded CNY 1 billion in China.

 

With the increasing living standards of Chinese people, the demand for eggs and poultry meat is growing accordingly, which promotes the development of poultry industry. In China and other neighboring countries, avian influenza, especially highly pathogenic avian influenza, has not been effectively controlled yet. For example, H5N1 highly pathogenic avian influenza broke out in North Korea in May 2013. Besides H5N1, H5 and H7 and other subtype highly pathogenic avian influenza are also highly possible to break out.

 

Therefore, it is predicted that the market size of avian influenza vaccines will keeping increasing and many animal healthcare enterprises attach attention to this market.

 

Purchase a copy of this report @ http://www.lifescienceindustryresearch.com/purchase?rname=22859


Through this report, the readers can acquire the following information:

Incidence Status of Avian InfluenzaStatus of Poultry Breeding in ChinaPolicy Environment and Government Procurement for Avian Influenza Vaccines in ChinaSupply and demand Status of Avian Influenza Vaccines in ChinaMajor Manufacturers of Avian Influenza Vaccines and the Operation Status in ChinaProspect of China Avian Influenza Vaccine Industry


The Following Enterprises and People Are Recommended to Purchase This Report:

Manufacturers and Trading Enterprises of Animal VaccinesPoultry Breeding EnterprisesManagement Organizations of Livestock IndustryInvestors and Research Institutes Concerned about the Avian Influenza Vaccine Industry

 

Table of Contents

 

1 Status of Global and China Avian Influenza Vaccine Markets

1.1 Relevant Concepts of Avian Influenza Vaccines

1.2 Brief Introductions to Epidemic Situation of Avian Influenza

 

2 Factors Influencing Development of China Avian Influenza Vaccine Industry, 2012-2013

2.1 Policies in China Animal Vaccine Industry

2.2 Status of China Poultry Industry, 2013

 

3 Operation Status of China Avian Influenza Vaccine Industry, 2009-2013

3.1 Supply of Avian Influenza Vaccines

3.2 Demand

3.3 Status of Free Avian Influenza Vaccines Provided by the Government

 

4 Major Manufacturers of Avian Influenza Vaccines in China, 2012-2013

4.1 QYH Biotech Company Limited

4.2 Qingdao Yebio Bioengineering Co., Ltd.

4.3 Zhaoqing Dahuanong Animal Health Products Co., Ltd.

4.4 Liaoning Yikang Biology Co., Ltd.

4.5 Harbin Weike Biotechnology Development Company

4.6 Harbin Pharmaceutical Group Biological Vaccines Co., Ltd.

4.7 Guangdong Winsun Pharmaceutical Co., Ltd.

4.8 Shandong Sinder Technology Co., Ltd.

4.9 Merial Nanjing Animal Health Co., Ltd

 

For other business research / market intelligence report on the ‘Pharmaceuticals’ market, contact sales@lifescienceindustryresearch.com  / Call +1 888 391 5441.

Rescooped by Mel Melendrez-Vallard from Virology News
Scoop.it!

Medicago successfully produces VLP vaccine candidate for H7N9 virus

Medicago successfully produces VLP vaccine candidate for H7N9 virus | Influenza | Scoop.it

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully produced a new VLP vaccine candidate  for the H7N9 virus that is responsible for the current influenza outbreak in China.

 

Influenza in birds graphic from Russell Kightley Media


Via Ed Rybicki
more...
Ed Rybicki's curator insight, May 10, 2013 6:34 AM

I keep saying, you gotta go green...and Medicago do, and have for H7N9.

 

Quicker than anyone else, evidently.  Truly impressive for plant production technology!

Rescooped by Mel Melendrez-Vallard from Virology News
Scoop.it!

GlaxoSmithKline’s quadrivalent influenza vaccine approved in UK and Germany

GlaxoSmithKline’s quadrivalent influenza vaccine approved in UK and Germany | Influenza | Scoop.it

GlaxoSmithKline’s quadrivalent influenza vaccine has been granted marketing authorisation in Germany and the UK. The four-strain vaccine is the first  to be approved in a European country for active immunisation of adults and children from three years of age for the prevention of influenza disease caused by the two influenza A and two influenza B virus subtypes contained within the vaccine.


Via Ed Rybicki
more...
No comment yet.
Rescooped by Mel Melendrez-Vallard from Virology News
Scoop.it!

Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics

During the 2009 H1N1 influenza pandemic, vaccines for the virus became available in large quantities only after human infections peaked. To accelerate vaccine availability for future pandemics, we developed a synthetic approach that very rapidly generated vaccine viruses from sequence data. Beginning with hemagglutinin (HA) and neuraminidase (NA) gene sequences, we combined an enzymatic, cell-free gene assembly technique with enzymatic error correction to allow rapid, accurate gene synthesis. We then used these synthetic HA and NA genes to transfect Madin-Darby canine kidney (MDCK) cells that were qualified for vaccine manufacture with viral RNA expression constructs encoding HA and NA and plasmid DNAs encoding viral backbone genes. Viruses for use in vaccines were rescued from these MDCK cells. We performed this rescue with improved vaccine virus backbones, increasing the yield of the essential vaccine antigen, HA. Generation of synthetic vaccine seeds, together with more efficient vaccine release assays, would accelerate responses to influenza pandemics through a system of instantaneous electronic data exchange followed by real-time, geographically dispersed vaccine production.

 


Via Ed Rybicki
more...
Ed Rybicki's curator insight, May 23, 2013 6:33 AM

So let's be clear: they made the vaccine SEED in 4 days, NOT the vaccine!  One would still then have to scale up production in mammalian cells - which is not trivial.

Rescooped by Mel Melendrez-Vallard from Virology News
Scoop.it!

Antigenic Drift of the Pandemic 2009 A(H1N1) Influenza Virus in a Ferret Model

Antigenic Drift of the Pandemic 2009 A(H1N1) Influenza Virus in a Ferret Model | Influenza | Scoop.it

Infection with influenza virus leads to significant morbidity and mortality. Annual vaccination may prevent subsequent disease by inducing neutralizing antibodies to currently circulating strains in the human population. To escape this antibody response, influenza A viruses undergo continuous genetic variation as they replicate, enabling viruses with advantageous antigenic mutations to spread and cause disease in naïve or previously immune or vaccinated individuals. To date, the 2009 pandemic virus (A(H1N1)pdm09) has not undergone significant antigenic drift, with the result that the vaccine remains well-matched and should provide good protection to A(H1N1)pdm09 circulating viruses. In this study, we induced antigenic drift in an A(H1N1)pdm09 virus in the ferret model. A single amino acid mutation emerged in the dominant surface glycoprotein, hemagglutinin, which had a multifaceted effect, altering both antigenicity and virus receptor specificity. The mutant virus could not be isolated using routine cell culture methods without the virus acquiring additional amino acid changes, yet was fit in vivo. The implications for surveillance of circulating influenza virus are significant as current assays commonly used to assess vaccine mismatch, as well as to produce isolates for vaccine manufacture, are biased against identification of viruses containing only this mutation.

 

Influenza virus graphic by Russell Kightley Media 


Via Ed Rybicki
more...
Ed Rybicki's curator insight, May 10, 2013 3:19 AM

There is a rather disturbing result in this paper: that is, that the mutation in the H1N1 HA that emerged in serial ferret transfers that was responsible for antigenic drift, resulted in a virus that could NOT be cultured by routine methods despite being quite happy in ferrets.  In fact, adapting the virus to culture meant it accumulated MORE mutations, meaning the thing they got out by "current assays" was NOT the same thing that was causing disease.

 

This is worrying for a number of reasons, not least of which is that informed decisions on probable vaccine efficacy are made as a result of such assays - and the vaccines themselves, in some cases.  And if what these decisions are based on is incorrect...?

 

Time for some better science here, people - like next-gen sequencing rather than isolation as a measure of what is causing disease!